Tscan Therapeutics is trading at $0.33, down 5.39%, with no new company-specific catalyst identified for September 25, 2026.
- The latest major company update remains the September 2 strategic reorganization, including a workforce reduction and paused ALLOHA-2 enrollment.
- Major indexes were broadly flat to modestly higher, so the decline is not clearly explained by overall market direction; trading volume information was unavailable.